Modality
mRNA
MOA
IL-17i
Target
PD-L1
Pathway
T-cell
RettMigraine
Development Pipeline
Preclinical
~Jun 2018
→ ~Sep 2019
Phase 1
~Dec 2019
→ ~Mar 2021
Phase 2
Jun 2021
→ Jan 2028
Phase 2Current
NCT06349590
233 pts·Migraine
2021-09→2025-06·Terminated
NCT05431966
344 pts·Rett
2021-06→2028-01·Completed
577 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-06-209mo agoPh3 Readout· Migraine
2028-01-111.8y awayPh3 Readout· Rett
Trial Timeline
Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028
P2/3
Complet…
P2/3
Termina…
Catalysts
Ph3 Readout
2025-06-20 · 9mo ago
Migraine
Ph3 Readout
2028-01-11 · 1.8y away
Rett
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06349590 | Phase 2/3 | Migraine | Terminated | 233 | EDSS |
| NCT05431966 | Phase 2/3 | Rett | Completed | 344 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| ABB-7516 | AbbVie | Phase 3 | PD-L1 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Olpatinib | GSK | Preclinical | PD-L1 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| BAY-3684 | Bayer | Approved | PD-L1 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Polatuximab | Nuvalent | Approved | PD-L1 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |